Business
Oxford Biomedica broadens its viral vector capa...
Oxford Biomedica broadens its viral vector capa....
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \n \n Oxford Biomedica broadens its viral vector capabilities with the launch of Oxford Biomedica Solutions, a full scope AAV business in Boston, following closing of its deal with Homology\n \n \n \n \n \n \n Unique platform offering capabilities from vector design and process development through to clinical trials is now available to new customers\n \n \n \n \n Oxford, UK – 11 March 2022: Oxford Biomedica plc (LSE:OXB) (\"Oxford Biomedica\" or the “Company\"), a leading gene and cell therapy group, is pleased to announce that it has completed its deal with Homology Medicines Inc. (Nasdaq: FIXX) (“Homology”), a genetic medicines company, to establish Oxford Biomedica Solutions LLC, a new US-based full scope, Adeno-Associated Virus (AAV) manufacturing and innovation business.\n The new Oxford Biomedica Solutions business is fully operational and offers a proprietary ‘plug and play’ platform that is capable of achieving both high titre and high product quality vector for customers. The platform has already been proven with three separate new product INDs, and the process has been run successfully at representative scale more than 600 times. High titre, high product quality, proven expertise, and speed are the foundation of the platform, and this differentiated new offering.\n The unique platform and fully integrated end-to-end capabilities, including from vector design and process development through to clinical trials, are now available to customers. This includes:\n \n Proprietary ‘plug and play’ process and manufacturing platform (i.e., same process for different transgenes and capsids) protected by intellectual property (IP)\n Team of approx.125 with complete end to end AAV expertise and experience\n 45+ successful 500L cGMP batches produced since 2019\n 3 x 500L single use bioreactors in multiple GMP suites operational\n Full CMC development scope: vector design, plasmid engineering, upstream, downstream, analytical development, formulation development\n cGMP operations scope: Manufacturing (Drug Substance & Drug Product), engineering, quality assurance, quality control, warehousing\n Platform successfully scaled to 2,000L\n Platform is a consistent and reliable serum free suspension cell culture and transfections system, and a two-column chromatography purification\n \n Oxford Biomedica’s presence in the US...